

PTO/SB/21 (09-04)

Approved for use through 07/31/2008. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	10/032,239
	Filing Date	December 21, 2001
	First Named Inventor	GUY V. TUCKER
	Art Unit	1617
	Examiner Name	WANG, SHENGJUN
Total Number of Pages in This Submission	Attorney Docket Number	0067.00

ENCLOSURES (Check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavit/declaration(s) <input checked="" type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): <b>APPEAL BRIEF</b>
Remarks		
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm Name	NEKTAR THERAPEUTICS	
Signature	<i>Guy V. Tucker</i>	
Printed name	GUY V. TUCKER	
Date	15 AUG 2005	Reg. No. 45,302

CERTIFICATE OF TRANSMISSION/MAILING		
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:		
Signature	<i>Karen J. Moir</i>	
Typed or printed name	KAREN J. MOIR	Date 08/15/2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**NEKTAR**

150 INDUSTRIAL ROAD  
SAN CARLOS, CA 94070-6256  
650-631-3100 • 650-631-3125 FAX

**FACSIMILE TRANSMITTAL SHEET**

TO: EXAMINER SHENGJUN WANG FROM: GUY V. TUCKER

COMPANY: U.S. Patent & Trademark Office PHONE NUMBER: 650-631-3100  
GROUP ART UNIT 1617

FAX NUMBER: 1-703-872-9302 FAX NUMBER: 650-631-3125

PHONE NUMBER: DATE: August 15, 2005

RE:

TOTAL NO. OF PAGES INCLUDING COVER: 15

☐ URGENT ☒ FOR REVIEW ☒ PLEASE COMMENT ☐ PLEASE REPLY ☐ PLEASE RECYCLE

NOTES/COMMENTS:

**NOTICE OF CONFIDENTIALITY**

This transmission is intended only for the use of the Addressee and may contain information that is:  
1. Subject to attorney/client privilege; 2. Attorney work product; or 3. Confidential. If you are not the  
intended recipient, you are hereby notified that any dissemination, distribution or copying of the  
information contained in this facsimile is strictly unauthorized and prohibited. If you have received this  
facsimile in error, please notify us immediately by collect phone to the sender named above.

CERTIFICATE OF MAILING

I hereby certify that the following papers are being facsimile  
transmitted to the Patent and Trademark Office  
at (703) 872-9302 on August 15, 2005

Signed: \_\_\_\_\_

Karen Moir

PATENT

.....  
In the United States Patent and Trademark Office  
.....

Applicant: Weickert et al.

Applicant's Ref: 0067.00

Application No: 10/032,239

Filed: December 21, 2001

Title: PULMONARY DELIVERY OF  
POLYENE ANTIFUNGAL AGENTS

Examiner: Wang, Shengjun

Group Art Unit: 1617

August 15, 2005  
San Carlos, California

APPEAL BRIEF

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In response to the Examiner's Final Rejection of July 14, 2004, the Applicant of  
the above-referenced patent application (hereinafter Appellant) hereby appeals to the Board of  
Patent Appeals and Interferences. Appellant requests the reversal of the Final Rejection.

**(1) *Real Party in Interest***

The real party in interest of the present application is Nektar Therapeutics (formerly Inhale Therapeutic Systems, Inc.), having a place of business at 150 Industrial Road; San Carlos, California 94707.

**(2) *Related Appeals and Interferences***

Appellant, Appellant's legal representative, and assignee are aware of no appeals or interferences which will directly affect or be directly affected by or have a bearing on the Board's decision in the present appeal.

**(3) *Status of Claims***

Claims 40-59 are presently pending in the case. Claims 40-59 have been finally rejected by the Examiner. The rejections of each of these claims are appealed.

**(4) *Status of Amendments***

No amendments after final have been filed. Applicant's amendment filed on April 16, 2004 has been entered.

**(5) *Summary of the Invention***

The present invention is directed to an inhaleable, spray dried powder formulation comprising a polyene antifungal agent, such as Amphotericin B. Polyenes possess very low solubilities in water and in conventional organic solvents. Thus, formulation of these compounds outside of dry mixing is extremely difficult. The solubility of the polyene can be increased under extreme conditions of pH. However, such conditions typically lead to significant levels of degradation of drug and are usually considered undesirable for the formation of powders for direct administration to the lung.

The present inventors were faced with the challenge of trying to find conditions for spray drying the highly insoluble drug, such as amphotericin B, that (i) did not promote high levels of degradation of drug, (ii) were economically practical, and (iii) resulted in the formation of aerosolizable particles suitable for inhalation.

The presently described and claimed invention relates to the result of this effort. Described are methods for spray drying polyene antifungal agents that result in the formation of

chemically stable yet highly dispersible powders. That is to say, the antifungal powders of the invention have excellent aerosol characteristics, such that they are reproducibly prepared and can be efficiently administered by inhalation to the lung, while exhibiting good chemical and physical stability.

In one aspect, the present invention provides a method for preparing a spray dried polyene for oral administration to the lung. The method includes the steps of dissolving a polyene antifungal agent in an acidified solvent and spray drying the polyene solution to form an inhaleable powder containing no more than about 10% polyene degradation products and characterized by an emitted dose of greater than 60%.

In another aspect, a method is provided for preparing a spray dried polyene powder for oral inhalation to the lung in which a polyene antifungal compound is suspended in an aqueous solvent to form a suspension, which is then wet milled, and spray dried. The resulting inhaleable powder contains no more than about 10% polyene degradation products (and typically less than that) and is characterized by an emitted dose greater than about 60%.

#### **(6) Issues**

There are presently two issues presented to the Board of Patent Appeals and Interferences for review:

(i) whether claims 40 and 42-59 are properly rejected under 35 U.S.C. 103(a) as being unpatentable over U.S. Patent 5,965,156 to Proffitt et al (hereinafter Proffitt et al), in view of PCT Publication WO 97/03649 to Staniforth et al (hereinafter Staniforth et al) and U.S. Patent 6,077,543 to Gordon et al (hereinafter Gordon et al); and

(ii) whether claim 41 is properly rejected under 35 U.S.C. 103(a) as being unpatentable over Proffitt et al, in view of Staniforth et al, Gordon et al, and further in view of U.S. Patent 4,016,254 to Seager (hereinafter Seager). [Note that it is believed that the Examiner intended to reject claim 41 under these grounds rather than claim 42 as typed in the Final Office Action.]

**(7) Grouping of claims**

Claim 40 stands and falls alone.

Claim 41 stands and falls alone. Claim 41 does not stand and fall with the other claims at least in its recitation of a wet milling step and the spray drying of a wet milled suspension.

Claims 42-56, 58 and 59 stand and fall together. These claims are to a spray-dried powder.

Claim 57 stands and falls alone. Claim 57 is to a composition comprising a polyene antifungal compound and a leucyl-containing excipient.

**(8) Argument**

Appellant believes each of claims 40-59 to be improperly rejected and to therefore be allowable for the at least the following reasons.

The Examiner improperly rejected independent claim 40 under 35 USC 103(a) as being unpatentable over Proffitt et al in view of Staniforth et al and Gordon et al. Claim 40 is to a dry powder for delivery by inhalation to the lungs, the dry powder produced by a method comprising: (i) dissolving a polyene antifungal compound in an acidified solvent to form an acidic polyene-containing solution, and (ii) spray drying said polyene-containing solution to form an inhaleable dry powder containing no more than about 10% polyene degradation products and characterized by an emitted dose greater than 60%. Proffitt et al does not disclose or suggest the powder as claimed, and the teachings of Staniforth et al and Gordon et al would not make a modification of Proffitt et al that arrives at the presently claimed invention obvious to one having ordinary skill in the art at the time the invention was made.

Proffitt et al does not render claim 40 unpatentable singly or in combination. Claim 40 is to, inter alia, a dry powder for delivery by inhalation to the lungs. In contrast, Proffitt et al discloses a liposomal polyene formulation that is dried and then re-hydrated so that it may be delivered intravenously to treat systemic fungal infections (see column 4 lines 20-54). Thus, Proffitt et al is not a dry powder for delivery by inhalation to the lungs. The fact that the Proffitt et al powder is dried at one time during its processing does not make it "a dry powder for delivery by inhalation to the lungs". For a dry powder to be deliverable to the lungs it can not be

a powder that is prone to hydration. Hydration during storage and/or during delivery in a humid environment will change the aerodynamic character of the powder and will limit the effectiveness of the active agent reaching the lungs. A powder such as the powder of Proffitt et al which is specifically designed to re-hydrate and not specifically designed for inhalation delivery would not be suitable for inhalation delivery. Furthermore, claim 40 recites that the emitted dose, that is the dose as defined on page 9 of Appellant's specification, is at least 60%. The presumption by the Examiner that the Proffitt et al powder which is not designed for inhalation delivery would have an emitted dose of at least 60% is, at best, speculative.

In addition, one of ordinary skill in the art would not have found it obvious to modify Proffitt in view of Staniforth and Gordon to change Proffitt et al's formulation to one that is a powder that is delivered to the lungs because doing so would go against the teachings of Proffitt et al. Proffitt et al is concerned with (1) a manner of making an injectable polyene formulation on a large scale and (2) the treatment of systemic fungal infections. Both of these teachings would be destroyed by the Examiner's proposed modification. Accordingly, not only is there no motivation for one of ordinary skill in the art to make the proposed modification to Proffitt et al, but the person of ordinary skill would be taught away from doing so. For at least these reasons, Applicant requests withdrawal of the rejection of claim 40.

Claim 41 is also not rendered unpatentable by Proffitt et al. Claim 41 is to a dry powder made by a process comprising, inter alia, suspending a polyene antifungal compound in an aqueous solvent to form a suspension and spray drying the suspension. Proffitt et al teaches a polyene solution and does not teach a polyene suspension that is spray dried. The teachings of Staniforth et al, Gordon et al, and Seager et al do not make up for the deficiencies of Proffitt, and one of ordinary skill in the art would not have found it obvious to modify the process of Proffitt et al based on these teachings, particularly in the absence of motivation to do so.

Independent claims 42, 57 and 58 are not rendered unpatentable by the applied references, either. Claims 42, 57 and 58 are to powder compositions suitable for oral inhalation to the lung comprising a therapeutically effective amount of a polyene antifungal compound. As discussed above, Proffitt et al does not disclose an inhaleable formulation and teaches away from a modification that would result in an inhaleable formulation. Therefore, claims 42, 57, and 58 and the claims depending therefrom are not rendered unpatentable by Proffitt et al, Staniforth et al, and Gordon et al.

For at least these reasons, Appellant requests that the rejection of claims 40-59 be overturned and requests an indication of the allowability thereof.

**(9) Appendix**

A copy of the claims involved in the appeal is attached hereto.

**Conclusion**


Thus, it is believed that all rejections made by the Examiner have been addressed and overcome by the above arguments. Therefore, all pending claims are allowable. A reversal is respectfully requested.

Should there be any questions, Appellant's representative may be reached at the number listed below.

Respectfully submitted,

NEKTAR THERAPEUTICS  
(formerly INHALE THERAPEUTIC  
SYSTEMS)

Dated: 15 AUG 2005

By:   
Guy V. Tucker  
Reg. No. 45,302

Please send all correspondence to:  
Guy Tucker  
Nektar Therapeutics  
(formerly Inhale Therapeutic Systems, Inc.)  
150 Industrial Road  
San Carlos, CA 94070  
Phone: (650) 620-5501  
Fax: (650) 631-3125



## APPENDIX

40. A dry powder for delivery by inhalation to the lungs, the dry powder produced by a method comprising:
- (i) dissolving a polyene antifungal compound in an acidified solvent to form an acidic polyene-containing solution, and
  - (ii) spray drying said polyene-containing solution to form an inhaleable dry powder containing no more than about 10% polyene degradation products and characterized by an emitted dose greater than 60%.
41. A dry powder produced by a method comprising:
- (i) suspending a polyene antifungal compound in an aqueous solvent to form a suspension,
  - (ii) wet milling the suspension from (i) to form a wet-milled suspension, and
  - (iii) spray drying the wet milled suspension to produce an inhaleable dry powder containing no more than about 10% polyene degradation products and characterized by an emitted dose greater than about 60%.
42. A spray-dried powder composition suitable for oral inhalation to the lung comprising a therapeutically effective amount of a polyene antifungal compound, wherein the composition comprises no more than about 10% polyene degradation products and is characterized by an emitted dose greater than about 60%.
43. The powder composition of claim 42, containing no more than about 5% polyene degradation products.
44. The powder composition of claim 42, wherein the powder comprises particles having an MMAD of less than about 5 microns.
45. The powder composition of claim 44, wherein the powder comprises particles having an MMAD of less than about 3.5 microns.
46. The powder composition of claim 42, which is non-proteinaceous.

47. The powder composition of claim 42, wherein said polyene is nystatin or amphotericin B.
48. The powder composition of claim 42, wherein said polyene is non-encapsulated.
49. The powder composition of claim 48, wherein said polyene is non-liposome and non-polymer encapsulated.
50. The powder composition of claim 42 substantially comprising neat polyene.
51. The powder composition of claim 42, further comprising a pharmaceutically acceptable excipient.
52. The powder composition of claim 51, wherein said excipient is selected from the group consisting of buffers, leucine, and trileucine.
53. The powder composition of claim 51, comprising at least about 30% by weight polyene.
54. The powder composition of claim 53, comprising at least about 50% by weight polyene.
55. The powder composition of claim 42, having a water content greater than about 4% by weight.
56. The powder composition of claim 55, having a water content ranging from about greater than 4% by weight to about 10% by weight.
57. A spray-dried powder composition suitable for oral inhalation to the lung comprising a therapeutically effective amount of a polyene antifungal compound and a leucyl-containing excipient comprising from 1 to 3 amino acid residues.

58. An aerosolized, spray-dried powder composition suitable for oral inhalation to the lung comprising a therapeutically effective amount of a polyene antifungal compound, wherein the composition comprises no more than about 10% polyene degradation products and is characterized by an emitted dose greater than about 60%.

59. A method for treating or preventing fungal infection in a subject in need thereof, said method comprising administering to said subject by oral inhalation a therapeutically effective amount of a spray dried powder composition of claim 42 in aerosolized form.

NOV.24.2005 12:21PM NEKTAR THERAPEUTICS

NO.810 P.16

P. 1

\* \* \* TRANSMISSION RESULT REPORT ( AUG.15.2005 3:07PM ) \* \* \*

DATE	TIME	ADDRESS	MODE	TIME	PAGE	RESULT	TTI NEKTAR THERAPEUTICS PERS. NAME	FILE
AUG.15.	3:04PM		USPTO TES	3'36"	P.15	OK		658

\*U# : BATCH  
: MEMORY  
: STANDARD  
: PC

C : CONFIDENTIAL  
L : SEND LATER  
D : DETAIL  
% : PC DIRECT

T# : TRANSFER  
: FORWARDING  
: FINE

D : POLLING  
: EOM  
Y : REDUCTION